Effect of theophylline on stent-related symptoms in patients undergoing Double-J ureteral stent insertion: a randomized controlled trial
International Urology and Nephrology · 2024
DOI: 10.1007/s11255-024-04049-x ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Urology and Nephrology, 2024. Verfasst von Alireza Pakdel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Stents, Theophylline. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To investigate the effect of oral theophylline on stent-related syndrome (SRS) after Double-J insertion. BACKGROUND: Double-J stent is widely using in many urological procedures. Infection, hematuria, and discomfort are some of common complication after stenting. Theophylline is a dimethylated xanthine that inhibits phosphodiesterase and blocks adenosine receptors. To relaxing effect of theophylline on smooth muscles and its effects on the urinary system, it seems it could reduce complications after inserting Double-J stent especially ureteral stent syndrome. METHOD: In this double-blind placebo-controlled randomized clinical trial, 67 patients were enrolled. Mean (SD) age of control and theophylline group was 51.8 (12.5) and 43.9 (10.4) years old, respectively. Patients were randomized into two groups of control and theophylline. All patients were stenting with silicon Double J. Theophylline group received 100 mg of theophylline, twice daily for 30 days, while control group received placebo. Stent symptoms were assessed by questionnaire and urine culture was performed before stent removal at removal day. Statistical analysis was performed using Chi-squared test and t test with P < 0.05 considered significant. Logistic regression models were fitted, crudely and adjusted for age and sex. RESULT: Of 67 eligible patients, 60 completed the study. Theophylline significantly decreased percentages of gross hematuria (P < 0.001), dysuria (P < 0.001), and urinary frequency (P < 0.001). Microscopic hematuria (P = 0.042) and chills (P = 0.042) also decreased after theophylline. CONCLUSION: Theophylline could be an effective and safe choice for reducing SRS among patients undergoing Double-J stent insertion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Section of Tissue Engineering and Stem Cells Therapy, Pediatric Urology and Regenerative Medicine Research Center, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mkaghamir@tums.ac.ir.
Zitieren
APA
Pakdel, A., Mohammadi, A., Chivaee, H., Shamshirgaran, A., Amirzargar, H., Farsani, R. M., Asgari, F., Khajavi, A., & Aghamir, S. M. K. (2024). Effect of theophylline on stent-related symptoms in patients undergoing Double-J ureteral stent insertion: a randomized controlled trial. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04049-x
Vancouver
Pakdel A, Mohammadi A, Chivaee H, Shamshirgaran A, Amirzargar H, Farsani RM, et al. Effect of theophylline on stent-related symptoms in patients undergoing Double-J ureteral stent insertion: a randomized controlled trial. International Urology and Nephrology. 2024. doi:10.1007/s11255-024-04049-x
BibTeX
@article{Pakdel2024,
author = {Pakdel, Alireza and Mohammadi, Abdolreza and Chivaee, Hossein and Shamshirgaran, Amirreza and Amirzargar, Hossein and Farsani, Reza Mohammadi and Asgari, Fardin and Khajavi, Alireza and Aghamir, Seyed Mohammad Kazem},
title = {Effect of theophylline on stent-related symptoms in patients undergoing Double-J ureteral stent insertion: a randomized controlled trial},
journal = {International Urology and Nephrology},
year = {2024},
doi = {10.1007/s11255-024-04049-x}
}
EUVIMED